2026 Global: Artificial Heart Market-Competitive Review (2032) report
Description
The 2026 Global: Artificial Heart Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
The artificial heart market features several leading firms with portfolios spanning total artificial heart (TAH) and ventricular assist devices (VADs). SynCardia Systems, LLC, headquartered in Tucson, United States, remains the sole commercial supplier of CardioWest total artificial heart and provides clinical support and training to transplant programs worldwide. Carmat SA, headquartered in Paris, France, has pursued a fully implantable bioprosthetic total artificial heart that integrates advanced biomaterials and hydraulic actuation to replicate native hemodynamics. Abiomed, Inc., based in Danvers, United States, specializes in circulatory support devices, including percutaneous and surgically implanted pumps such as the Impella family, and heart assist platforms. Edwards Lifesciences Corporation, headquartered in Irvine, United States, is a major provider of structural heart solutions and VAD interfaces, with products that complement TAH programs through hemodynamic monitoring and biocompatible components. These firms collectively drive device development, regulatory pathways, and clinical trial frameworks that shape patient access and outcomes.
Medtronic plc, headquartered in Dublin, Ireland, represents a global leader in cardiovascular therapies, with HVAD legacy devices and adjunct facilities that support large-scale clinical trials across North America, Europe, and Asia. Abbott Laboratories, based in Abbott Park, United States, maintains a broad portfolio that includes durable circulatory support and ambulatory pump systems, and has integrated its cardiac devices within a holistic heart failure ecosystem. HeartWare International, Inc., with a Framingham, United States address, historically supplied compact VADs that supported rapid ambulation and reduced hospital stays for advanced heart failure patients; following the acquisition by Medtronic, HVAD technology remains a focal pivot within the combined portfolio and regulatory strategy. Berlin Heart GmbH, headquartered in Berlin, Germany, specialized in pediatric and bridging total artificial heart solutions, introducing EXCOR and related assist devices that remain central in pediatric centers worldwide. These product lines support bridging therapy and durable device programs across multiple continents.
LivaNova PLC, headquartered in London, United Kingdom, integrates Sorin Group heritage with a broad portfolio of cardiovascular devices, including ventricular assist platforms and related therapies that complement clinical pathways for advanced heart failure. The company's strategic emphasis emphasizes international distribution networks, regulatory approvals across major markets, and ongoing research collaborations to optimize patient outcomes in bridging and destination therapy. Terumo Corporation, based in Tokyo, Japan, contributes a comprehensive line of perfusion systems, vascular access products, and ECMO components that support a wide range of cardiac interventions, including devices used in conjunction with VAD programs and total artificial heart trials. Together, these firms round out a diversified ecosystem in which hybrid therapy strategies combining mechanical support, biocompatible materials, and patient-specific care pathways are central to modern cardiac care. As the field evolves, collaboration across geographies and disciplines will determine adoption, safety, and survival for patients dependent on artificial heart technologies worldwide.
The artificial heart market features several leading firms with portfolios spanning total artificial heart (TAH) and ventricular assist devices (VADs). SynCardia Systems, LLC, headquartered in Tucson, United States, remains the sole commercial supplier of CardioWest total artificial heart and provides clinical support and training to transplant programs worldwide. Carmat SA, headquartered in Paris, France, has pursued a fully implantable bioprosthetic total artificial heart that integrates advanced biomaterials and hydraulic actuation to replicate native hemodynamics. Abiomed, Inc., based in Danvers, United States, specializes in circulatory support devices, including percutaneous and surgically implanted pumps such as the Impella family, and heart assist platforms. Edwards Lifesciences Corporation, headquartered in Irvine, United States, is a major provider of structural heart solutions and VAD interfaces, with products that complement TAH programs through hemodynamic monitoring and biocompatible components. These firms collectively drive device development, regulatory pathways, and clinical trial frameworks that shape patient access and outcomes.
Medtronic plc, headquartered in Dublin, Ireland, represents a global leader in cardiovascular therapies, with HVAD legacy devices and adjunct facilities that support large-scale clinical trials across North America, Europe, and Asia. Abbott Laboratories, based in Abbott Park, United States, maintains a broad portfolio that includes durable circulatory support and ambulatory pump systems, and has integrated its cardiac devices within a holistic heart failure ecosystem. HeartWare International, Inc., with a Framingham, United States address, historically supplied compact VADs that supported rapid ambulation and reduced hospital stays for advanced heart failure patients; following the acquisition by Medtronic, HVAD technology remains a focal pivot within the combined portfolio and regulatory strategy. Berlin Heart GmbH, headquartered in Berlin, Germany, specialized in pediatric and bridging total artificial heart solutions, introducing EXCOR and related assist devices that remain central in pediatric centers worldwide. These product lines support bridging therapy and durable device programs across multiple continents.
LivaNova PLC, headquartered in London, United Kingdom, integrates Sorin Group heritage with a broad portfolio of cardiovascular devices, including ventricular assist platforms and related therapies that complement clinical pathways for advanced heart failure. The company's strategic emphasis emphasizes international distribution networks, regulatory approvals across major markets, and ongoing research collaborations to optimize patient outcomes in bridging and destination therapy. Terumo Corporation, based in Tokyo, Japan, contributes a comprehensive line of perfusion systems, vascular access products, and ECMO components that support a wide range of cardiac interventions, including devices used in conjunction with VAD programs and total artificial heart trials. Together, these firms round out a diversified ecosystem in which hybrid therapy strategies combining mechanical support, biocompatible materials, and patient-specific care pathways are central to modern cardiac care. As the field evolves, collaboration across geographies and disciplines will determine adoption, safety, and survival for patients dependent on artificial heart technologies worldwide.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
